- Home
- URGN vs EVN Comparison
URGN vs EVN Comparison
Compare URGN & EVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- EVN
- Stock Information
- Founded
- URGN 2004
- EVN 1998
- Country
- URGN United States
- EVN United States
- Employees
- URGN N/A
- EVN N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- EVN Investment Bankers/Brokers/Service
- Sector
- URGN Health Care
- EVN Finance
- Exchange
- URGN Nasdaq
- EVN Nasdaq
- Market Cap
- URGN 547.1M
- EVN 441.5M
- IPO Year
- URGN 2017
- EVN N/A
- Fundamental
- Price
- URGN $12.84
- EVN $10.92
- Analyst Decision
- URGN Strong Buy
- EVN
- Analyst Count
- URGN 5
- EVN 0
- Target Price
- URGN $44.50
- EVN N/A
- AVG Volume (30 Days)
- URGN 764.9K
- EVN 101.2K
- Earning Date
- URGN 11-12-2024
- EVN 01-01-0001
- Dividend Yield
- URGN N/A
- EVN 4.78%
- EPS Growth
- URGN N/A
- EVN N/A
- EPS
- URGN N/A
- EVN 0.34
- Revenue
- URGN $85,011,000.00
- EVN N/A
- Revenue This Year
- URGN $16.49
- EVN N/A
- Revenue Next Year
- URGN $57.58
- EVN N/A
- P/E Ratio
- URGN N/A
- EVN $29.94
- Revenue Growth
- URGN 17.22
- EVN N/A
- 52 Week Low
- URGN $10.60
- EVN $8.64
- 52 Week High
- URGN $20.70
- EVN $10.45
- Technical
- Relative Strength Index (RSI)
- URGN 49.60
- EVN 48.36
- Support Level
- URGN $11.84
- EVN $10.76
- Resistance Level
- URGN $13.54
- EVN $11.04
- Average True Range (ATR)
- URGN 0.82
- EVN 0.08
- MACD
- URGN 0.08
- EVN -0.02
- Stochastic Oscillator
- URGN 65.88
- EVN 51.67
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.